CAMPANI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.678
AS - Asia 3.057
EU - Europa 2.640
SA - Sud America 382
Continente sconosciuto - Info sul continente non disponibili 127
AF - Africa 90
OC - Oceania 41
Totale 10.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.575
RU - Federazione Russa 1.031
CN - Cina 1.002
SG - Singapore 844
IT - Italia 808
HK - Hong Kong 317
KR - Corea 310
BR - Brasile 296
VN - Vietnam 226
IE - Irlanda 149
FR - Francia 120
FI - Finlandia 96
SE - Svezia 96
DE - Germania 87
GB - Regno Unito 79
IN - India 78
CA - Canada 71
PL - Polonia 67
BD - Bangladesh 66
JO - Giordania 48
ID - Indonesia 47
NL - Olanda 44
AU - Australia 41
AR - Argentina 33
IQ - Iraq 19
JP - Giappone 16
ZA - Sudafrica 15
EC - Ecuador 13
NG - Nigeria 13
RO - Romania 13
TR - Turchia 13
UZ - Uzbekistan 13
ES - Italia 11
CI - Costa d'Avorio 10
CO - Colombia 10
PK - Pakistan 10
UA - Ucraina 10
EG - Egitto 9
MX - Messico 9
PE - Perù 8
NP - Nepal 7
PY - Paraguay 7
BJ - Benin 6
CL - Cile 6
DZ - Algeria 6
KE - Kenya 6
MA - Marocco 6
VE - Venezuela 6
AT - Austria 5
HN - Honduras 5
PH - Filippine 5
TN - Tunisia 5
CR - Costa Rica 4
IL - Israele 4
JM - Giamaica 4
OM - Oman 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
SA - Arabia Saudita 3
TH - Thailandia 3
AM - Armenia 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
GT - Guatemala 2
HU - Ungheria 2
KG - Kirghizistan 2
MY - Malesia 2
RS - Serbia 2
SC - Seychelles 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
UY - Uruguay 2
AL - Albania 1
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GN - Guinea 1
GR - Grecia 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
MZ - Mozambico 1
NA - Namibia 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 9.881
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.038
Singapore 669
Ashburn 604
Hefei 402
Seoul 308
Hong Kong 276
San Jose 179
Dublin 149
Milan 141
Beijing 113
Council Bluffs 113
Florence 102
Los Angeles 99
Ho Chi Minh City 94
Chandler 71
Moscow 70
Fairfield 69
Rome 64
Warsaw 63
Buffalo 62
Kent 60
Helsinki 56
Lauterbourg 51
New York 51
Hanoi 50
Altamura 42
Lawrence 41
Munich 41
London 39
Shanghai 39
The Dalles 39
Melbourne 37
Jakarta 36
Houston 33
Paris 30
Cambridge 28
São Paulo 28
Bengaluru 25
Dallas 25
Woodbridge 24
Arezzo 23
Bologna 23
Lappeenranta 23
Princeton 22
Wilmington 22
Boardman 21
Boston 21
Mumbai 21
Naples 21
Seattle 21
Frankfurt am Main 17
Atlanta 16
Turku 16
Tokyo 14
Toronto 14
West Jordan 14
Abuja 13
Amman 13
Montreal 12
Orem 12
Turin 12
Brooklyn 11
Chicago 11
Genoa 11
Haiphong 11
Abidjan 10
City of London 10
Rio de Janeiro 10
San Diego 10
Ann Arbor 9
Chennai 9
Tashkent 9
Timisoara 9
Da Nang 8
Hangzhou 8
Porto Alegre 8
Washington 8
Amsterdam 7
Buenos Aires 7
Guangzhou 7
Medford 7
Miano 7
Modena 7
Newark 7
Nuremberg 7
Parma 7
Piscataway 7
Redondo Beach 7
Bari 6
Belo Horizonte 6
Cotonou 6
Figino 6
Istanbul 6
Johannesburg 6
Prato 6
Riverside 6
San Francisco 6
Biên Hòa 5
Calgary 5
Caxias do Sul 5
Totale 6.130
Salva come PNG Salva come JPEG
Nome #
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 282
Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis 241
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 228
A large rheumatoid nodule mimicking hepatic malignancy 223
Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives 213
Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives 209
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 206
Circulating biomarkers of response to systemic treatments in advanced hepatocellular 202
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma 198
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey 197
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 196
Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center 192
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 192
Practical insights into chronic management of hepatic Wilson's disease 191
Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma 186
Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells 185
CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 182
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 176
Metabolic disorders across hepatocellular carcinoma in Italy 173
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients 172
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 163
Transjugular intrahepatic Porto-systemic shunt positively influences the composition and metabolic functions of the gut microbiota in cirrhotic patients 160
The changing scenario of hepatocellular carcinoma in Italy: an update 159
Main factors influencing long-term outcomes of liver transplantation in 2022 156
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 155
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 155
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 152
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 152
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 151
An atypical case of palmo-plantar erythrodysesthesia related to cabozantinib 150
The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma 150
Pattern of macrovascular invasion in hepatocellular carcinoma 150
Needs evaluation questionnaire for liver disease: a novel assessment of unmet needs in patients with chronic liver disease 146
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 143
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma 142
Fragility index of positive phase II and III randomized clinical trials of treatments for hepatocellular carcinoma (2002-2022) 140
Prevalence of nutritional risk and malnutrition during and after hospitalization for COVID-19 infection: Preliminary results of a single-centre experience 139
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab 137
Quick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution? 137
Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma 136
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab 136
Time-varying mHAP III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization 133
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC 132
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC 132
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 130
Elusive Hepatic Nodules 126
Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs 126
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 125
Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver 122
Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes 121
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab 120
The upward trajectory of the UEG journal: Next Generation Trainee Editors 119
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA 118
Systemic treatment of hepatocellular carcinoma: the times they are a-changin' 117
Biological therapies in patients with liver disease: are they really lifesavers? 116
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 107
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 104
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice 103
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma 103
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 102
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors 94
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care 93
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 88
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab 60
Predictors of non‐transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection 53
Probiotics and the gut-liver axis 49
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 42
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab 20
Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma 19
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma 11
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 10
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 9
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 9
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma 7
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data 7
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 7
Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease 7
Correction to: CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib 7
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes 6
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 6
null 2
Totale 10.015
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.794
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.794
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022179 0 1 7 2 2 13 0 10 31 34 32 47
2022/2023586 36 111 31 8 27 109 83 43 70 31 28 9
2023/2024669 23 39 56 18 35 71 42 198 26 71 58 32
2024/20253.230 98 310 178 447 851 458 95 131 144 93 162 263
2025/20264.634 533 704 692 415 368 158 476 187 253 255 190 403
2026/2027461 188 273 0 0 0 0 0 0 0 0 0 0
Totale 10.015